Sunshine Biopharma announces issuance of notice of allowance for patent application covering Adva-27a in Canada

The allowed claims in Canada are nearly identical to those already issued in the US (US Patent Number 8,236,935) where Sunshine Biopharma is the exclusive licensee.

Sunshine Biopharma has previously announced preclinical results showing that Adva-27a has excellent pharmacokinetics profile in rats and remarkable cytotoxic activity against a variety of multidrug resistant cancer cells including breast cancer cells and pancreatic cancer cells.

Adva-27a appears to be unique in its ability to destroy multidrug resistant cancer cells. Sunshine Biopharma is moving forward with the next steps in the development of Adva-27a which include GMP manufacturing, IND-enabling studies and Phase I clinical trials.

Sunshine Biopharma CEO Dr Steve N. Slilaty noted that allowance of the Adva-27a patent application in Canada constitutes yet another stamp of approval for the validity and innovative aspects of Adva-27a.

"We are very excited about moving our Adva-27a to the next stage of development and the prospects of it becoming a new weapon in the battle against cancer," Dr Slilaty added.

Adva-27a is Sunshine Biopharma’s lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancer cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012).

Adva-27a is currently in the IND-Enabling stage of development. The original U.S. patent covering Adva-27a was issued on 7 August 2012 under US patent number 8,236,935. The company is planning a Phase I clinical trial of Adva-27a for pancreatic cancer in parallel to the Phase I clinical trial of Adva-27a for multidrug resistant breast cancer to be conducted at McGill University’s Jewish General Hospital in Montreal (Canada).